---
schema_version: "secwatch.filing_event.v1"
accession: "0001140361-25-042304"
form_type: "8-K"
ticker: "FEMY"
cik: "0001339005"
company_name: "FEMASYS INC"
filed_at: "2025-11-14T23:59:59+00:00"
generated_at: "2026-05-16T19:46:49.641969+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Femasys Q3 sales up 31% to $729K; FDA clears FemBloc final pivotal trial; $12M financing extends runway

## Summary
- Net loss $4.19M ($0.10/sh) vs $5.41M ($0.24/sh) a year ago on lower R&D spend.
- Sales rose 31.4% YoY to $729,394, driven by FemBloc product sales.
- FDA IDE approval to commence final phase of FemBloc pivotal trial for U.S. approval.
- Closed $12M secured convertible note offering with warrants for up to $58M total potential funding.
- Cash $4.6M at Q3 end; with recent financing, runway extended into September 2026.

## SEC filing metadata
- accession: 0001140361-25-042304
- form_type: 8-K
- ticker: FEMY
- cik: 0001339005
- company_name: FEMASYS INC
- filed_at: 2025-11-14T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1339005/000114036125042304/0001140361-25-042304-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1339005/000114036125042304/ef20059086_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001140361-25-042304
- JSON: https://secwatch.observer/filing/0001140361-25-042304.json
- Plain text: https://secwatch.observer/filing/0001140361-25-042304.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.